Akebia Therapeutics (AKBA) Total Current Liabilities (2013 - 2026)

Akebia Therapeutics (AKBA) has 14 years of Total Current Liabilities data on file, last reported at $173.9 million in Q1 2026.

• On a quarterly basis, Total Current Liabilities rose 90.61% year-over-year to $173.9 million in Q1 2026; TTM through Mar 2026 was $173.9 million, a 90.61% increase from a year earlier, with the FY2025 full-year figure at $162.9 million, up 101.37% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $173.9 million, up from $162.9 million in the prior quarter.
• Over the last five years, Total Current Liabilities for AKBA reached as high as $258.5 million in Q1 2022 and fell as low as $65.7 million in Q3 2024.
• Historically, Total Current Liabilities has averaged $128.1 million across 5 years, with a median of $107.3 million in 2024.
• Across the five-year window, Total Current Liabilities tumbled 66.09% in 2023 and jumped 102.98% in 2025, its largest moves.
• Year by year, Total Current Liabilities stood at $129.5 million in 2022, then fell by 22.9% to $99.9 million in 2023, then fell by 18.98% to $80.9 million in 2024, then jumped by 101.37% to $162.9 million in 2025, then rose by 6.72% to $173.9 million in 2026.
• Per Business Quant data, the three most recent Total Current Liabilities figures were $173.9 million in Q1 2026, $162.9 million in Q4 2025, and $133.4 million in Q3 2025.